Literature DB >> 26658225

Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes.

Vaishali Dixit1, Amanda Moore2, Hong Tsao2, Niresh Hariparsad2.   

Abstract

Long-term coculture models of hepatocytes are promising tools to study drug transport, clearance, and hepatoxicity. In this report we compare the basal expression of drug disposition genes and the inductive response of prototypical inducers (rifampin, phenobarbital, phenytoin) in hepatocyte two-dimensional monocultures and the long-term coculture model (HepatoPac). All the inducers used in the study increased the expression and activity of CYP3A4, CYP2B6 and CYP2C enzymes in the HepatoPac cultures. The coculture model showed a consistent and higher induction of CYP2C enzymes compared with the monocultures. The EC50 of rifampin for CYP3A4 and CYP2C9 was up to 10-fold lower in HepatoPac than the monocultures. The EC50 of rifampin calculated from the clinical drug interaction studies correlated well with the EC50 observed in the HepatoPac cultures. Owing to the long-term stability of the HepatoPac cultures, we were able to directly measure a half-life (t1/2) for both CYP3A4 and CYP2B6 using the depletion kinetics of mRNA and functional activity. The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours. The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins. This is the first study to our knowledge to report the turnover rate of CYP2B6 in human hepatocytes. The data presented here demonstrate that the HepatoPac cultures have the potential to be used in long-term culture to mimic complex clinical scenarios.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26658225     DOI: 10.1124/dmd.115.067173

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Advances in Engineered Human Liver Platforms for Drug Metabolism Studies.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  Drug Metab Dispos       Date:  2018-08-22       Impact factor: 3.922

2.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Liver 'organ on a chip'.

Authors:  Colin H Beckwitt; Amanda M Clark; Sarah Wheeler; D Lansing Taylor; Donna B Stolz; Linda Griffith; Alan Wells
Journal:  Exp Cell Res       Date:  2017-12-29       Impact factor: 3.905

Review 4.  Microfabrication of liver and heart tissues for drug development.

Authors:  Grace E Brown; Salman R Khetani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

5.  Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids.

Authors:  Tomas Smutny; Veronika Bernhauerova; Lucie Smutna; Jurjen Duintjer Tebbens; Petr Pavek
Journal:  Arch Toxicol       Date:  2021-10-23       Impact factor: 5.153

6.  New and effective method to develop primary hepatocytes from liver cancer patients.

Authors:  Jia-Yan Li; Li-Li Wang; Jing Fan; Du-Xian Liu; Jian-Bo Han; Yu-Feng Zhang; Dan-Dan Yin; Yong-Xiang Yi
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-26

Review 7.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

8.  Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.

Authors:  Yun-Ting Zhu; Yi-Fan Zhang; Jin-Fang Jiang; Yong Yang; Li-Xia Guo; Jing-Jing Bao; Da-Fang Zhong
Journal:  Invest New Drugs       Date:  2021-01-27       Impact factor: 3.651

Review 9.  Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.

Authors:  Stephen Fowler; Peter N Morcos; Yumi Cleary; Meret Martin-Facklam; Neil Parrott; Michael Gertz; Li Yu
Journal:  Curr Pharmacol Rep       Date:  2017-02-01

Review 10.  Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.